Related Experiment Videos
Waldenström's macroglobulinemia: long-term results with the M-2 protocol
Cancer Investigation
|January 11, 1991
Summary
The M-2 protocol shows promise for treating Waldenström's macroglobulinemia, with a majority of patients experiencing prolonged survival and well-tolerated treatment. Further research is needed to refine therapy recommendations and identify survival predictors.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Waldenström's macroglobulinemia is a rare B-cell lymphoproliferative disorder.
- Symptomatic patients often require treatment to manage disease burden and complications.
Purpose of the Study:
- To evaluate the efficacy and tolerability of the M-2 protocol in patients with symptomatic Waldenström's macroglobulinemia.
- To assess long-term survival outcomes and identify potential prognostic factors.
Main Methods:
- A cohort of 33 patients with symptomatic Waldenström's macroglobulinemia received the M-2 protocol (BCNU, cyclophosphamide, vincristine, melphalan, prednisone).
- Treatment was administered over extended periods, with dose adjustments based on response and toxicity.
- Clinical and laboratory parameters were monitored throughout the study.
Main Results:
- Twenty-seven of 33 patients (82%) responded to therapy, with 21 (64%) achieving partial responses.
- Projected 10-year survival was 58%, with 10 patients alive at or beyond 6 years.
- Treatment was generally well-tolerated, with manageable hematologic toxicity and common side effects including peripheral neuropathy.
Conclusions:
- The M-2 protocol demonstrates potential for inducing prolonged survival in Waldenström's macroglobulinemia.
- Further clinical trials are warranted to optimize treatment strategies and identify predictive factors for survival.